Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose...
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
August 06, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024 07:00 ET
|
Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
April 24, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards...
Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...